Warfarin and Flavonoids Do Not Share the Same Binding Region in Binding to the IIA Subdomain of Human Serum Albumin

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2017 Jul 12

PMID 28696372

Citations 14

Authors

Hrvoje Rimac

Claire Dufour

Zeljko Debeljak

Branka Zorc

Mirza Bojic

Affiliations

Soon will be listed here.

Abstract

Human serum albumin (HSA) binds a variety of xenobiotics, including flavonoids and warfarin. The binding of another ligand to the IIA binding site on HSA can cause warfarin displacement and potentially the elevation of its free concentration in blood. Studies dealing with flavonoid-induced warfarin displacement from HSA provided controversial results: estimated risk of displacement ranged from none to serious. To resolve these controversies, in vitro study of simultaneous binding of warfarin and eight different flavonoid aglycons and glycosides to HSA was carried out by fluorescence spectroscopy as well as molecular docking. Results show that warfarin and flavonoids do not share the same binding region in binding to HSA. Interactions were only observed at high warfarin concentrations not attainable under recommended dosing regimes. Docking experiments show that flavonoid aglycons and glycosides do not bind at warfarin high affinity sites, but rather to different regions within the IIA HSA subdomain. Thus, the risk of clinically significant warfarin-flavonoid interaction in binding to HSA should be regarded as negligible.

Citing Articles

Effects of Chrysin and Chrysin-7-sulfate on Ochratoxin A-Albumin Interactions and on the Plasma and Kidney Levels of the Mycotoxin in Rats.

Poor M, Dombi A, Fliszar-Nyul E, Pedroni L, Dellafiora L ACS Omega. 2024; 9(15):17655-17666.

PMID: 38645364 PMC: 11024961. DOI: 10.1021/acsomega.4c01738.

Native mass spectrometry analysis of conjugated HSA and BSA complexes with various flavonoids.

Alexander N, McDonald L, Wesdemiotis C, Pang Y Analyst. 2024; 149(6):1929-1938.

PMID: 38376111 PMC: 10926777. DOI: 10.1039/d3an02070c.

Anti-Aggregative and Protective Effects of Vicenin-2 on Heat and Oxidative Stress-Induced Damage on Protein Structures.

Patane G, Lombardo L, Putaggio S, Tellone E, Ficarra S, Barreca D Int J Mol Sci. 2023; 24(24).

PMID: 38139052 PMC: 10743203. DOI: 10.3390/ijms242417222.

Antibiotics and Lipid-Modifying Agents: Potential Drug-Drug Interactions and Their Clinical Implications.

Spanakis M, Alon-Ellenbogen D, Ioannou P, Spernovasilis N Pharmacy (Basel). 2023; 11(4).

PMID: 37624085 PMC: 10457919. DOI: 10.3390/pharmacy11040130.

Structural Analysis and Protein Binding of Cephalosporins.

Kanis E, Parks J, Austin D ACS Pharmacol Transl Sci. 2023; 6(1):88-91.

PMID: 36654755 PMC: 9841772. DOI: 10.1021/acsptsci.2c00168.

References

Di Bari L, Ripoli S, Pradhan S, Salvadori P . Interactions between quercetin and warfarin for albumin binding: A new eye on food/drug interference. Chirality. 2009; 22(6):593-6. DOI: 10.1002/chir.20794. View

Zsila F, Bikadi Z, Simonyi M . Probing the binding of the flavonoid, quercetin to human serum albumin by circular dichroism, electronic absorption spectroscopy and molecular modelling methods. Biochem Pharmacol. 2003; 65(3):447-56. DOI: 10.1016/s0006-2952(02)01521-6. View

Epps D, Raub T, Caiolfa V, Chiari A, Zamai M . Determination of the affinity of drugs toward serum albumin by measurement of the quenching of the intrinsic tryptophan fluorescence of the protein. J Pharm Pharmacol. 1999; 51(1):41-8. DOI: 10.1211/0022357991772079. View

Dufour C, Dangles O . Flavonoid-serum albumin complexation: determination of binding constants and binding sites by fluorescence spectroscopy. Biochim Biophys Acta. 2005; 1721(1-3):164-73. DOI: 10.1016/j.bbagen.2004.10.013. View

Dangles O, Dufour C, Manach C, Morand C, Remesy C . Binding of flavonoids to plasma proteins. Methods Enzymol. 2001; 335:319-33. DOI: 10.1016/s0076-6879(01)35254-0. View

Bren U, Oostenbrink C . Cytochrome P450 3A4 inhibition by ketoconazole: tackling the problem of ligand cooperativity using molecular dynamics simulations and free-energy calculations. J Chem Inf Model. 2012; 52(6):1573-82. DOI: 10.1021/ci300118x. View

Yacobi A, Udall J, Levy G . Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin Pharmacol Ther. 1976; 19(5 Pt 1):552-8. DOI: 10.1002/cpt1976195part1552. View

Morris G, Huey R, Lindstrom W, Sanner M, Belew R, Goodsell D . AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009; 30(16):2785-91. PMC: 2760638. DOI: 10.1002/jcc.21256. View

Petitpas I, Bhattacharya A, Twine S, East M, Curry S . Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I. J Biol Chem. 2001; 276(25):22804-9. DOI: 10.1074/jbc.M100575200. View

10.

Schmidt S, Gonzalez D, Derendorf H . Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci. 2009; 99(3):1107-22. DOI: 10.1002/jps.21916. View

11.

Jensen B, Chin P, Roberts R, Begg E . Influence of adult age on the total and free clearance and protein binding of (R)- and (S)-warfarin. Br J Clin Pharmacol. 2012; 74(5):797-805. PMC: 3495144. DOI: 10.1111/j.1365-2125.2012.04259.x. View

12.

Omidvar Z, Parivar K, Sanee H, Amiri-Tehranizadeh Z, Baratian A, Saberi M . Investigations with spectroscopy, zeta potential and molecular modeling of the non-cooperative behaviour between cyclophosphamide hydrochloride and aspirin upon interaction with human serum albumin: binary and ternary systems from multi-drug therapy. J Biomol Struct Dyn. 2011; 29(1):181-206. DOI: 10.1080/07391102.2011.10507382. View

13.

DArcy P, McElnay J . Drug interactions involving the displacement of drugs from plasma protein and tissue binding sites. Pharmacol Ther. 1982; 17(2):211-20. DOI: 10.1016/0163-7258(82)90012-2. View

14.

Boulton D, Walle U, Walle T . Extensive binding of the bioflavonoid quercetin to human plasma proteins. J Pharm Pharmacol. 1998; 50(2):243-9. DOI: 10.1111/j.2042-7158.1998.tb06183.x. View

15.

Yamasaki K, Maruyama T, Takadate A, Suenaga A, Kragh-Hansen U, Otagiri M . Characterization of site I of human serum albumin using spectroscopic analyses: locational relations between regions Ib and Ic of site I. J Pharm Sci. 2004; 93(12):3004-12. DOI: 10.1002/jps.20203. View

16.

Bors W, Michel C, Stettmaier K . Antioxidant effects of flavonoids. Biofactors. 1997; 6(4):399-402. DOI: 10.1002/biof.5520060405. View

17.

Poor M, Boda G, Needs P, Kroon P, Lemli B, Bencsik T . Interaction of quercetin and its metabolites with warfarin: Displacement of warfarin from serum albumin and inhibition of CYP2C9 enzyme. Biomed Pharmacother. 2017; 88:574-581. DOI: 10.1016/j.biopha.2017.01.092. View

18.

Lee K, Woo H, Bang O, On Y, Kim J, Lee S . How to use warfarin assays in patient management: analysis of 437 warfarin measurements in a clinical setting. Clin Pharmacokinet. 2014; 54(5):517-25. DOI: 10.1007/s40262-014-0219-1. View

19.

He X, Carter D . Atomic structure and chemistry of human serum albumin. Nature. 1992; 358(6383):209-15. DOI: 10.1038/358209a0. View

20.

Sudlow G, Birkett D, Wade D . The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol. 1975; 11(6):824-32. View